valbenazine Ingrezza
Selected indexed studies
- Valbenazine. (, 2006) [PMID:37748010]
- Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial. (Lancet Neurol, 2023) [PMID:37210099]
- Valbenazine (Ingrezza) for tardive dyskinesia. (Med Lett Drugs Ther, 2017) [PMID:28520698]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Valbenazine. (2006) pubmed
- Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial. (2023) pubmed
- KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia. (2017) pubmed
- Valbenazine for Tardive Dyskinesia. (2017) pubmed
- Valbenazine: First Global Approval. (2017) pubmed
- Treatment Recommendations for Tardive Dyskinesia. (2019) pubmed
- Tics and Tourette Syndrome. (2019) pubmed
- Valbenazine (Ingrezza) for tardive dyskinesia. (2017) pubmed
- VMAT2 Inhibitors and the Path to Ingrezza (Valbenazine). (2018) pubmed
- Pharmaceutical Approval Update. (2017) pubmed